TRIANA Biomedicines is a venture-backed biopharmaceutical company leading a transformative approach to discovering and developing novel small molecules to treat disease. Our technology enables us to identify molecules that promote the interaction between a target and another protein in a way that alters the fate or function of the target protein. These innovative “molecular glues” allow us to treat disease in entirely new ways by pursuing highly disease-relevant targets that have long been considered undruggable or inadequately addressed.
Our target-first, rational approach to molecular glue discovery lets us consider a wide range of therapeutic applications for our products. Our initial focus on targeted protein degradation is driven by our desire to discover and develop groundbreaking new cancer medicines. TRIANA Biomedicines is headquartered in Waltham, Massachusetts, and has established internal laboratory work as well as key collaborations with academia and industry partners.
Total Funding: N/A
Funding Stage: N/A
Business Stage: Scaling Up
Market: B2C, B2B
Company Size: 1 to 25
Founded: N/A
For AI/ML Startup Founders
Get introduced to VC/PE/CVC investors
For Investors at VC/PE firms
Get introduced to AI/ML Startup founders or founders at Triana Biomedicines
Patrick Trojer
Chief Executive Officer & President
Director of Finance
Waltham, MA
Principal Scientist, Lead Discovery
Senior scientist, cell biology with flow cytometry (Oncology)
